Global Newsroom

Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel.

CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Australia and New Zealand.

CSL Plasma U.S. collection centers are preparing to undergo implementation of newly cleared Rika Plasma Donation System, with limited market release beginning in Colorado centers.

With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors

CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd.

Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures, exploring opportunities to collaborate around disruptive technologies and build relationships with entrepreneurial founders.

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors

$2.5 Million Funding Available to Australian Biomedical Researchers

New Patent Box policy will benefit domestic commercialisation of medical research

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL